Company Overview and News

3
Renegade Exploration trades higher as activity heats up in the Yandal Greenstone Belt

2018-06-07 proactiveinvestors.com.au
Renegade Exploration Ltd (ASX:RNX) continues to attract investors as the company's exploration plans in the world-class Yandal Greenstone Belt advance.
EAR DRG BKHRF AYR NSR SCEXF NST BLK NHRNY SAR NESRF

3
Renegade Exploration revs up for major drilling program in premier gold country

2018-05-21 proactiveinvestors.com.au
Renegade Exploration Ltd (ASX:RNX) will get the drill bit spinning in early June targeting gold at its Yandal East project in the gold-rich Yandal Greenstone Belt of Western Australia.
EAR DRG BKHRF AYR NSR SCEXF NST BLK NHRNY SAR NESRF

3
Renegade Exploration leveraged to gold news flow from world-class Yandal Greenstone Belt

2018-05-10 proactiveinvestors.com.au
Renegade Exploration Ltd (ASX:RNX) is focused on finding another major gold project in the elephant country that is the Yandal Greenstone Belt near Wiluna in Western Australia’s North Eastern Goldfields.
EAR DRG BKHRF AYR NSR SCEXF NST BLK NHRNY SAR NESRF

1
Nexus Minerals hits high-grade gold at GT6 prospect in Western Australia’s Eastern Goldfields

2018-05-08 proactiveinvestors.com.au
Nexus Minerals Ltd (ASX:NXM) has enhanced its golden future after receiving a wide high-grade gold intersection from GT6 prospect of the Pinnacles project in Western Australia’s Eastern Goldfields.
SCEXF EGS EGDD NXM ESGFF SAR

1
Nexus Minerals searches for the next Karari at Pinnacles Gold Project

2018-04-19 proactiveinvestors.com.au
Nexus Minerals Ltd (ASX:NXM) is actively exploring for gold deposits on its highly prospective tenement package in the Eastern Goldfields of Western Australia.
SCEXF EGS EGDD NXM ESGFF SAR

14
ASX finishes flat on banks

2018-04-17 theage.com.au
The Australian market ended flat on Tuesday, with the benchmark once again failing to stretch to a third consecutive session of gains.
OISHY SCEXF MS.PRE VLRSY MS.PRF MS.PRG VRL MS.PRA WHC VLRDF MDBKY OISHF MPL MS.PRI MS.PRK VLRDY MS SAR OSH

14
ASX finishes flat on banks

2018-04-17 smh.com.au
The Australian market ended flat on Tuesday, with the benchmark once again failing to stretch to a third consecutive session of gains.
OISHY SCEXF MS.PRE VLRSY MS.PRF MS.PRG VRL MS.PRA WHC VLRDF MDBKY OISHF MPL MS.PRI MS.PRK VLRDY MS SAR OSH

0
Markets Live: ASX lifted by miners

2018-04-17 theage.com.au
Following the string of revelations of misconduct at the royal commission, AMP's new CEO will certainly have a challenge on their hands.
SCEXF VLRSY VLRDY VRL VLRDF SAR

0
Markets Live: ASX lifted by miners

2018-04-17 smh.com.au
Following the string of revelations of misconduct at the royal commission, AMP's new CEO will certainly have a challenge on their hands.
SCEXF VLRSY VLRDY VRL VLRDF SAR

1
Nexus Minerals completes acquisition of Wallbrook Gold Project near Saracen's Carosue Dam

2018-04-06 proactiveinvestors.com.au
Nexus Minerals Ltd (ASX:NXM) has completed the acquisition of Wallbrook Gold Project from Saracen Mineral Holdings Limited (ASX:SAR) for consideration of about 1.5 million Nexus shares.
SCEXF EGS EGDD NXM ESGFF SAR

1
Nexus Minerals begins drilling as it seeks to enhance gold potential at Pinnacles

2018-04-04 proactiveinvestors.com.au
Nexus Minerals Ltd (ASX:NXM) has started an extensive aircore drilling program at the GT6 prospect of its Pinnacles Gold Project in Western Australia’s Eastern Goldfields.
SCEXF EGS EGDD NXM ESGFF SAR

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Silicon Investor Message Boards

This table lists all message boards related to ASX:SAR / SARACEN MINERAL HOLDINGS LIMITED on message board site Silicon Investor.

Sarissa Resources, Inc. (SRSR) Finisar - FNSR
Arrowhead Resarch Sarissa Shareholders
Sarissa Resources Sarah Palin for President 2008
SARS and Avian Flu Sarah Palin - Is She Hot or Not?
Quasar Aerospace Industries, Inc. SRSR - Sarissa Resources Inc.